Salient Surgical Technologies

Salient Surgical Technologies Newswire (Page 7)

Comprehensive Real-Time News Feed for Salient Surgical Technologies. (Page 7)

Results 121 - 140 of 651 in Salient Surgical Technologies

  1. UPDATE 1-Medtronic gets U.S. antitrust OK to buy Covidien with divestitureRead the original story

    Nov 26, 2014 | Reuters

    Medtronic Inc has won U.S. antitrust approval to buy Dublin-based Covidien Plc on condition that it sell its drug-coated balloon catheter business, the Federal Trade Commission said on Wednesday. Medtronic, a Minneapolis-based maker of defibrillators, spinal implants, insulin pumps and other products, said previously that it expected the transaction to close in early 2015.

    Comment?

  2. Competition Bureau Reaches Consent Agreement in Medtronic/Covidien DealRead the original story

    Nov 26, 2014 | Sys-Con Media

    The Competition Bureau announced today that it has reached a consent agreement with Medtronic Inc. and Covidien plc that resolves the Bureau's concerns related to Medtronic's proposed acquisition of Covidien. Both companies sell medical devices in Canada for the treatment of various conditions.

    Comment?

  3. Dividend Aristocrats In Focus Part 44: MedtronicRead the original story w/Photo

    Nov 26, 2014 | Seeking Alpha

    Medtronic was founded in 1949. The company has grown into the largest publicly traded medical technology company with a market cap of $71 billion.

    Comment?

  4. Value-Based Healthcare As Seen By Medtronic's CEORead the original story w/Photo

    Nov 24, 2014 | Medical Device/Diagnostic Ind.

    In a wide-ranging interview at a Minneapolis conference, Medtronic's CEO describes what value-based healthcare is and why it is important. LIfeScience Alley CEO Shaye Mandle interviews Medtronic CEO Omar Ishrak at LifeScience Alley's annual conference in Minneapolis last week.

    Comment?

  5. Jefferies Group Raises Medtronic Price Target to $83.00Read the original story w/Photo

    Nov 19, 2014 | AmericanBankingNews.com

    The firm currently has a "buy" rating on the stock. Jefferies Group's price target would suggest a potential upside of 14.53% from the stock's previous close.

    Comment?

  6. Oppenheimer Raises Medtronic Price Target to $78.00Read the original story w/Photo

    Nov 19, 2014 | AmericanBankingNews.com

    The firm currently has an "outperform" rating on the stock. Oppenheimer's price objective suggests a potential upside of 7.63% from the company's current price.

    Comment?

  7. Medtronic plans to complete Covidien dealRead the original story w/Photo

    Nov 18, 2014 | USA Today

    Medical device giant Medtronic Tuesday reiterated its plan to buy Ireland-based rival Covidien in a deal expected to cut the Minneapolis-based company's future U.S. tax bills. Medtronic plans to complete Covidien deal Medical device giant Medtronic Tuesday reiterated its plan to buy Ireland-based rival Covidien in a deal expected to cut the Minneapolis-based company's future U.S. tax bills.

    Comment?

  8. Analysts like Medtronic moves, earningsRead the original story w/Photo

    Nov 18, 2014 | Business Journal

    A slight increase in spinal revenue, momentum from new products and progress in its acquisition of Covidien have analysts looking positively at Medtronic Inc. The company reported its fiscal second quarter earnings this morning, with sales of $4.3 billion, a five percent year-over-year increase. Medtronic Spine's revenue increased 1 percent to $746 million.

    Comment?

  9. Medtronic sees flat spine revenueRead the original story w/Photo

    Nov 18, 2014 | Business Journal

    Despite flat revenue for its Memphis-based spinal division, Medtronic Inc. saw a 5 percent increase in its fiscal second quarter, while net income dropped. Medtronic reported sales of $4.3 billion for the fiscal second quarter of 2015, and earnings of $828 million, a decline from $902 million in the fiscal second quarter of 2014.

    Comment?

  10. Medtronic reports lower earnings as Covidien deal moves to close in '15Read the original story w/Photo

    Nov 18, 2014 | Modern Healthcare

    Medtronic , a Minneapolis-based medical-device manufacturer, said profits fell again in the second quarter of its fiscal 2015, reporting an 8.2% drop in net earnings to $828 million. One-time events, such as charges for a pending major acquisition, accounted for the decline, the company contended.

    Comment?

  11. Medtronic Earnings In Line; Sales Guidance UpRead the original story w/Photo

    Nov 18, 2014 | Investor's Business Daily

    Medtronic was up 3.5% in early trading in the stock market today , near 71.50. Earlier, Medtronic stock rose as high as 72.26, touching an all-time high for the fifth time in the past 10 trading days.

    Comment?

  12. Medtronic say Irish move is still onRead the original story

    Nov 18, 2014 | Business World

    Medtronic posted a quarterly profit that was in line with analyst expectations, helped by sales of new heart devices, and said its $42.9 billion purchase of Irish-based hospital products maker Covidien remains on track to close early next year. Changes in U.S. tax rules aimed at curbing a spate of so-called tax inversion acquisitions have caused investors to question whether the deal would proceed after companies such as drugmaker AbbVie and Irish competitor Shire dropped plans to merge.

    Comment?

  13. Medtronic Meets 2Q Profit ForecastsRead the original story w/Photo

    Nov 18, 2014 | CBS Local

    TV is part of CBS Television Stations, a division of CBS Corp. and one of the largest network-owned station groups in the country. Click here for WCCO-TV news stories Send us your breaking news tips [...] 830 WCCO Welcome to News Radio 830 WCCO on CBSMinnesota.com! WCCO is part of CBS Radio, a division of CBS Corp. and one of the largest network-owned station groups in the country.

    Comment?

  14. UPDATE 2-Medtronic profit meets expectations; Covidien deal on trackRead the original story

    Nov 18, 2014 | Reuters

    Medtronic Inc posted a quarterly profit that was in line with analyst expectations, helped by sales of new heart devices, and said its $42.9 billion purchase of hospital products maker Covidien Plc remains on track to close early next year. Changes in U.S. tax rules aimed at curbing a spate of so-called tax inversion acquisitions have caused investors to question whether the deal would proceed after companies such as drugmaker AbbVie Inc and Irish competitor Shire Plc dropped plans to merge.

    Comment?

  15. Medtronic Reports Second Quarter EarningsRead the original story

    Nov 18, 2014 | PR-inside.com

    The company reported worldwide second quarter revenue of $4.366 billion, compared to the $4.194 billion reported in the second quarter of fiscal year 2014, an increase of 5 percent on a constant currency basis, after adjusting for a $38 million foreign currency impact, or 4 percent as reported. As reported, second quarter GAAP net earnings were $828 million, or $0.83 per diluted share, a decrease of 8 percent and 7 percent, respectively, over the same period in the prior year.

    Comment?

  16. Medtronic and Covidien Shareholder Meetings Scheduled for January 6, 2015Read the original story

    Nov 17, 2014 | Freshnews

    MINNEAPOLIS & DUBLIN, Ireland -- -- Medtronic, Inc. and Covidien plc announced that following a hearing today before the Irish High Court the companies have scheduled shareholder meetings for Tuesday, January 6, 2015, in connection with the pending acquisition of Covidien by Medtronic. Medtronic's special shareholder meeting will be held on January 6, 2015 at 8:00 a.m. local time at the Hyatt Regency, 1300 Nicollet Mall, Minneapolis, MN, 55403.

    Comment?

  17. Medtronic Studies Show Cardiac Resynchronization Therapy Extends Life, Reduces Hospital ReadmissionsRead the original story

    Nov 16, 2014 | PressReleasePoint

    Data Demonstrate Clinical and Economic Value of Underutilized Treatment for Heart Failure Patients at American Heart Association's Scientific Sessions 2014 MINNEAPOLIS and CHICAGO - Nov. 16, 2014 - Medtronic, Inc. today announced new data supporting the clinical and economic value of its cardiac resynchronization therapy devices for the treatment of heart failure, including a significant reduction in all-cause 30-day readmissions after heart failure hospitalizations. Additionally, heart failure patients who benefited early from CRT lived longer and consumed fewer hospital resources than patients who did not experience early benefit from the therapy.

    Comment?

  18. Medtronic Stock on Pace To Reach New HighsRead the original story w/Photo

    Nov 13, 2014 | Barron's

    Medtronic could speed up its dividend growth by spring, closing the gap between its current 1.8% yield and the higher yields of health-care stalwarts like Johnson & Johnson, which pays 2.6%.

    Comment?

  19. Medtronic Study Reveals Significant Heart Rhythm Disorders Occurring...Read the original story

    Nov 13, 2014 | PressReleasePoint

    Data Presented at Kidney Week 2014 Find Irregular Heartbeats Occur Frequently Around Hemodialysis Sessions MINNEAPOLIS and PHILADELPHIA - Nov. 13, 2014 - Medtronic, Inc. today revealed the results of a new study which found that atrial fibrillation and bradycardia-two common heart rhythm disorders-occurred at higher than expected, and clinically significant, rates in patients with end-stage renal disease undergoing hemodialysis. Moreover, these worrisome rhythm disorders appeared to correlate with patients' dialysis cycles, occurring immediately before, during and after their dialysis sessions.

    Comment?

  20. Medtronic Adds to Endurant 'AAA' Stent Graft SystemRead the original story

    Nov 12, 2014 | PressReleasePoint

    New Bifurcated Component Leverages Proven Design of Predicate Device and Expands Anatomical Customization Options for Endovascular Repair of Abdominal Aortic Aneurysms MINNEAPOLIS -- Nov. 12, 2014 -- The global leader in medical technology for endovascular aortic repair , Medtronic, Inc. today announced the launch in Europe and the United States of the Endurant IIs AAA stent graft, which recently received the CE mark and U.S. Food and Drug Administration approval to be used in the minimally invasive treatment of abdominal aortic aneurysms. The new device joins the Endurant family of products, which have been used to treat more than 160,000 patients worldwide since they were first introduced in Europe in 2008.

    Comment?